Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

actual prostate cancer tissue and to examine the correlation between immune responses in the tissue versus those in the circulating blood."

"Given the evidence of a survival benefit seen in our previous Phase 3 trial, D9901, in patients with advanced prostate cancer, we believe PROVENGE may also have applicability to men with earlier stages of the disease. This trial will help us better understand the mechanism of action and biology of PROVENGE, as well as evaluate the potential of PROVENGE in patients at high-risk for recurrence of their cancer following radical prostatectomy," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer of Dendreon. "We are highly focused on taking the steps necessary to get PROVENGE through the FDA approval process in order to get this important immunotherapy to prostate cancer patients with advanced disease who do not have any other reasonable options. We are on track to complete the interim analysis of our ongoing Phase 3 IMPACT trial during the latter half of this year."

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined wit
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... and PRETORIA, South Africa , ... , cancer kills more people than HIV/AIDS, malaria and tuberculosis ... and 40 percent can be cured with the right treatment[3]. ... African nations are working to build up their radiation therapy ... of all cancer patients worldwide would benefit from radiation therapy[4] ...
(Date:5/6/2015)... DUBLIN , May 05, 2015 Research ... announced the addition of the "Chromatography (Instruments ... report to their offering. Chromatography ... and identifying the component of a complex mixture ... Over the decades the scientists have considered chromatography ...
(Date:5/6/2015)... DUBLIN , May 06, 2015 Research ... announced the addition of the "Global Insulin ... offering. Highly advanced technology like ultrasound ... of modern insulin patches. Depending upon the type ... be out of reach of several patients. In ...
Breaking Medicine Technology:Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Global Chromatography (Instruments and Reagents) Market 2015 - Forecasts to 2019 2Global Insulin Patch Market Opportunity Analysis 2015 2
... Nov. 15, 2011 Coronado Biosciences, Inc., a company ... of autoimmune diseases and cancer, today announced financial results ... The Company,s cash and cash equivalents as of ... a net loss of approximately $29.6 million for the ...
... and PHILADELPHIA, Nov. 15, 2011 Niiki Pharma Inc. ... lead product, NKP-1339, at the AACR-NCI-EORTC International Conference on ... CA, November 12-16, 2011. The data ... in both in vitro and in ...
Cached Medicine Technology:Coronado Biosciences Reports Third Quarter 2011 Financial Results 2Coronado Biosciences Reports Third Quarter 2011 Financial Results 3Coronado Biosciences Reports Third Quarter 2011 Financial Results 4Coronado Biosciences Reports Third Quarter 2011 Financial Results 5Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents 2
(Date:5/6/2015)... 2015 Edvance360 LMS-SN , a ... won the Software & Information Industry Association's (SIIA) ... "Best Postsecondary Learning Management Solution" category. Edvance360 LMS-SN ... finalists for this award seven years running, continued proof ... in the industry. , "The honor of being ...
(Date:5/6/2015)... Miami, FL (PRWEB) May 06, 2015 Qushanna ... baby outside a nearby drug treatment center in Florida while ... on May 4th. New surveillance tapes released by CBS4’s ... 7am, without her baby. Doby’s child is around one year ... baby crying and shivering outside was not named. The residents ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
(Date:5/6/2015)... 06, 2015 “ SideChef ” was featured on ... at the latest and coolest applications on the market for iOS, ... expert, conducted the app review and shared with viewers how this ... day when to be a good navigator people had to know ... now everyone is a master navigator. Well what if people could ...
(Date:5/6/2015)... Austin, Texas (PRWEB) May 06, 2015 ... expert-level finance, HR, IT and operational support to optimize ... veteran Consulting CFOs, Jack Lynch and Michael Scheaffer. Both ... diverse finance and leadership experience. , “We are ... says Ellen Wood, vcfo CEO. “Leveraging their background in ...
Breaking Medicine News(10 mins):Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 2Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 3Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:An Application to Guide Users through Recipes Was Featured on NewsWatch Television 2Health News:vcfo Adds Two Senior Executives to Growing Team 2
... have long thought that limiting the calories a person consumes ... cancers. But research using mice suggests// that body composition ... is key to reducing cancer risks. ,In ... important to controlling cancer risks than how many or how ...
... American biologist has developed a backpack that reduces the weight ... by Lawrence Rome, a biology professor at the University of ... emergency workers, reported UPI news wire. ,It uses ... the burden of weight. The cords suspend the load at ...
... to a study published in the the journal SLEEP, ... depressive symptoms// and comorbid anxiety disorders compared with children ... most effective care, parents of sleep-disturbed children are advised ... issue a referral to a sleep specialist for comprehensive ...
... marine snail have gotten an unprecedented look at brain mechanisms, ... creature are far from sluggish. ,At any given time ... as Aplysia, more than 10,000 genes are active, according to ... journal Cell. The findings suggest that acts of learning or ...
... In hemophilia, a mutated gene prevents the production of ... such genetic diseases, when they exist//, may consist of ... what if the body could be induced to begin ... the abilities that are lacking? ,Prof. Yair Reisner ...
... at Purdue University have used a new technique ... dangerous E. coli, without time-consuming// treatments usually required. ... DESI, could be used to create a new ... from food safety to homeland security, said R. ...
Cached Medicine News:Health News:Body Composition Is Key Player in Controlling Cancer Risks 2Health News:Link Between Insomnia and Hypersomnia, Depression in Children 2Health News:How Many Genes Does It Take to Learn? Lessons from Sea Slugs 2Health News:How Many Genes Does It Take to Learn? Lessons from Sea Slugs 3Health News:A Transplant in Time - Scientists ID Window for Tissue Transplant 2Health News:New Technique to Identify Bacteria for Food Safety 2Health News:New Technique to Identify Bacteria for Food Safety 3
Gendron ophthalmic eye surgery stretcher....
... Membraneblue is a dye developed to ... visualize the I.L.M. and E.R.M.'s. By injecting ... intraocular membranes are stained without diluting the ... under air, the blue stained membranes can ...
Rhex-ID (Trypan Blue 0.8 mg)....
... color monitor produces superb ... icons for easier identification ... choices for measurement. Allows ... smaller pupils than conventional ...
Medicine Products: